Correlation Between Larimar Therapeutics and Genelux Common

Can any of the company-specific risk be diversified away by investing in both Larimar Therapeutics and Genelux Common at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Larimar Therapeutics and Genelux Common into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Larimar Therapeutics and Genelux Common, you can compare the effects of market volatilities on Larimar Therapeutics and Genelux Common and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Larimar Therapeutics with a short position of Genelux Common. Check out your portfolio center. Please also check ongoing floating volatility patterns of Larimar Therapeutics and Genelux Common.

Diversification Opportunities for Larimar Therapeutics and Genelux Common

-0.32

Correlation Coefficient

Larimar Therapeutics  Genelux Common

Very good diversification

The 3 months correlation between Larimar and Genelux is -0.32. Overlapping area represents the amount of risk that can be diversified away by holding Larimar Therapeutics and Genelux Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Genelux Common and Larimar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Larimar Therapeutics are associated (or correlated) with Genelux Common. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Genelux Common has no effect on the direction of Larimar Therapeutics i.e., Larimar Therapeutics and Genelux Common go up and down completely randomly.

Pair Corralation between Larimar Therapeutics and Genelux Common

Given the investment horizon of 90 days Larimar Therapeutics is expected to under-perform the Genelux Common. But the stock apears to be less risky and, when comparing its historical volatility, Larimar Therapeutics is 1.54 times less risky than Genelux Common. The stock trades about -0.15 of its potential returns per unit of risk. The Genelux Common is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  240.00  in Genelux Common on December 29, 2024 and sell it today you would earn a total of  68.00  from holding Genelux Common or generate 28.33% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Larimar Therapeutics  vs.  Genelux Common

Larimar Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Larimar Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Genelux Common

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Genelux Common are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak essential indicators, Genelux Common showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Larimar Therapeutics and Genelux Common

The main advantage of trading using opposite Larimar Therapeutics and Genelux Common positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Larimar Therapeutics position performs unexpectedly, Genelux Common can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genelux Common will offset losses from the drop in Genelux Common's long position.

The idea behind Larimar Therapeutics and Genelux Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.